Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SYNE3 antisense RNA 1 (SYNE3-AS1)
- Target
- SYNE3-AS1
- Molecular classification
- long non-coding RNA (lncRNA), antisense RNA
01
Overview
SYNE3 antisense RNA 1 (SYNE3-AS1, also known as AL133467.1) is a human long non-coding RNA (lncRNA) transcribed antisense to the SYNE3 gene. It is part of the lncRNA family, specifically functioning as an antisense RNA, which may allow it to regulate the expression of the adjacent or overlapping SYNE3 gene. SYNE3 encodes nesprin-3, a component of the LINC complex important for nuclear-cytoskeletal linkages and implicated in cancer cell biology. While SYNE3-AS1 is cataloged in human gene databases and is classified as a lncRNA, no published literature establishes SYNE3-AS1 as a therapeutic target, disease biomarker, or object of drug interactions[3][5]. Most available data simply note its genomic location and class as a non-coding RNA, without functional or clinical correlation. This lack of data applies specifically to SYNE3-AS1 and not to the protein-coding gene SYNE3, which has emerging associations with cancer and cell biology but is a separate entity[2][4].
- Other names
- AL133467.1SYNE3-AS1
02
Biological functions
regulation of gene expression (likely at the post-transcriptional level), potentially modulating SYNE3 expressiongeneral roles proposed for antisense lncRNAs include impact on mRNA stability, translation, and RNA/protein interactions[3][5]
03
Disease associations
insufficient direct evidence for disease association with SYNE3-AS1 specificallyhowever, lncRNAs in general may be involved in cancer and other diseases via regulatory networks[3]
Beyond the preview
Go deeper on SYNE3 antisense RNA 1 (SYNE3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNE3 antisense RNA 1 (SYNE3-AS1).